Report leads to questioning drug manufacturers

This+is+the+exterior+of+the+Mallinckrodt+Pharmaceuticals+office+in+St.+Louis+as+of+July+1%2C+2013.+A+recent+report+has+prompted+new+question+for+drug+manufacturers.+

This is the exterior of the Mallinckrodt Pharmaceuticals office in St. Louis as of July 1, 2013. A recent report has prompted new question for drug manufacturers.

Sadie Kuhn, Staff Writer

A recent report released for a federal court case and analyzed by the Associated Press found that many generic drugmakers, such as Mallinckrodt Pharmaceuticals, produced a large amount of the opioids taken during the height of the Opioid Crisis. Mallinckrodt employees answered lawyers’ questions under oath in what was expected to be the first federal trial over the toll of opioid makers and the pharmacies that distributed them . The company ended up settling with the plaintiffs — the Ohio counties of Cuyahoga and Summit. Other drug-centered companies are pushing the settle thousands of similar cases due to another opioid trial scheduled to begin next month in Central Islip, New York. 

With the new information regarding Mallinckrodt people have begun to look into their bonus structure for many of their sales employees. It’s now understood that Mallinckrodt would give out a six figure bonus and the chance for vacations to Hawaii, the Caribbean or Mexico to employees that hit or beat sales goals for prescription opioids and other drugs. This is the same staff that was in charge of reporting any sales of its painkillers that appeared to be suspicious which was meant included distributors or pharmacies requesting extreme volumes of its most potent formulas. However, none were ever pushed to level needed to report to authorities. 

Print Friendly, PDF & Email